Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
All currency values in $ millions unless otherwise noted
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | -$1 | $3 | $4 | $1 |
| Operating Income | -$166 | -$161 | -$135 | -$133 |
| Non-Operating | ||||
| Net Interest Expense | -$0 | -$0 | -$0 | -$0 |
| Income Tax Expense | -$1 | -$1 | $0 | $0 |
| Net Income | ||||
| Net Income | -$165 | -$149 | -$129 | -$126 |
| Per Share Data | ||||
| Revenue Per Share | -$0.02 | $0.11 | $0.16 | $0.01 |
| EPS (Basic) | -$5.46 | -$5.39 | -$4.73 | -$1.32 |
| EPS (Diluted) | -$5.46 | -$5.39 | -$4.73 | -$1.32 |
| Shares Outstanding | 30.3M | 27.6M | 27.3M | 95.4M |
Odyssey Therapeutics (ODTX) generated about -$697,000.00 in revenue and -$165 million in net income (a 23,720.2% net margin) over the trailing twelve months, growing at roughly 69.4% a year. Figures are from SEC filings; this is analysis, not investment advice.
Odyssey Therapeutics generated about -$697,000.00 in revenue over the trailing twelve months. Revenue has grown at roughly 69.4% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Odyssey Therapeutics reported about -$165 million in net loss over the trailing twelve months, a net margin of roughly 23,720.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Odyssey Therapeutics runs an operating margin of about 23,764.0%, a net margin of about 23,720.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Odyssey Therapeutics's revenue has compounded at roughly 69.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ODTX's margins and free cash flow. This is analysis from SEC filings, not investment advice.